HomePHS • FRA
add
Photocure ASA
Nakaraang pagsara
€4.18
Sakop ng araw
€4.22 - €4.22
Sakop ng taon
€4.01 - €6.13
P/E ratio
-
Dividend yield
-
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (NOK) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 120.22M | 11.79% |
Gastos sa pagpapatakbo | 114.55M | 9.62% |
Net na kita | -3.47M | 27.61% |
Net profit margin | -2.88 | 35.28% |
Kita sa bawat share | -0.13 | 27.78% |
EBITDA | 5.03M | 50.58% |
Aktuwal na % ng binabayarang buwis | 29.87% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (NOK) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 291.05M | 14.11% |
Kabuuang asset | 720.47M | 2.11% |
Kabuuang sagutin | 220.74M | -6.73% |
Kabuuang equity | 499.73M | — |
Natitirang share | 27.11M | — |
Presyo para makapag-book | 0.23 | — |
Return on assets | -0.76% | — |
Return on capital | -1.05% | — |
Cash Flow
Net change in cash
| (NOK) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -3.47M | 27.61% |
Cash mula sa mga operasyon | 34.53M | 298.30% |
Cash mula sa pag-invest | 2.43M | 196.27% |
Cash mula sa financing | -12.90M | -28.49% |
Net change in cash | 24.06M | 718.75% |
Malayang cash flow | 25.14M | 5,846.43% |
Tungkol
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Itinatag
1993
Website
Mga Empleyado
102
